Neumora Therapeutics (NASDAQ:NMRA) Earns Outperform Rating from Analysts at Mizuho

Mizuho initiated coverage on shares of Neumora Therapeutics (NASDAQ:NMRAFree Report) in a research note issued to investors on Monday, MarketBeat Ratings reports. The firm issued an outperform rating and a $20.00 price target on the stock.

Other equities research analysts also recently issued reports about the company. William Blair reaffirmed an outperform rating on shares of Neumora Therapeutics in a research report on Friday, April 12th. Royal Bank of Canada reiterated an outperform rating and set a $31.00 price target on shares of Neumora Therapeutics in a research report on Thursday, March 28th. Finally, JPMorgan Chase & Co. upped their price objective on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an overweight rating in a research report on Monday, March 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $22.25.

Check Out Our Latest Research Report on NMRA

Neumora Therapeutics Price Performance

Shares of NMRA opened at $10.76 on Monday. The company’s fifty day moving average price is $9.62 and its 200-day moving average price is $13.21. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRAGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share for the quarter, hitting the consensus estimate of ($0.34). As a group, equities research analysts predict that Neumora Therapeutics will post -1.46 EPS for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Large investors have recently made changes to their positions in the company. Citigroup Inc. acquired a new stake in Neumora Therapeutics in the 3rd quarter valued at about $203,000. SG Americas Securities LLC acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $108,000. Strs Ohio acquired a new position in Neumora Therapeutics during the fourth quarter worth $54,000. New York State Common Retirement Fund acquired a new position in Neumora Therapeutics during the fourth quarter worth $118,000. Finally, Amalgamated Bank acquired a new stake in shares of Neumora Therapeutics in the 4th quarter worth $29,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

(Get Free Report)

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Featured Articles

Analyst Recommendations for Neumora Therapeutics (NASDAQ:NMRA)

Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.